|
A government advisory panel is
considering a new approach to insulin. Instead of injecting
insulin to control the blood sugar levels of diabetics, this new
method will allow users to inhale their medicine.
Exubera is being
developed by Pfizer, Sanofi-Aventis, and Nektar Therapeutics.
Thus far the FDA is concerned about the effects that Exubera
might have on the lungs of patients, especially those that
smoke, or those with lung disease.
Soon we will have an interactive
forum covering all aspects today's drug issues. Until then you
can e-mail us your comments and we will post them to the forum
as soon as it is active. E-mail
Us!
|
| Last
year, the drug industry spent $4.02 billion on ads, up 23
percent from 2003 and 62 percent from 2000, according to
consulting firm IMS Health.
CNN |
|
|
